120 related articles for article (PubMed ID: 6342123)
21. Complement activation and complement control proteins in acute pancreatitis.
Whicher JT; Barnes MP; Brown A; Cooper MJ; Read R; Walters G; Williamson RC
Gut; 1982 Nov; 23(11):944-50. PubMed ID: 6922819
[TBL] [Abstract][Full Text] [Related]
22. The functional state of the complement system in leprosy.
Gomes GI; Nahn EP; Santos RK; Da Silva WD; Kipnis TL
Am J Trop Med Hyg; 2008 Apr; 78(4):605-10. PubMed ID: 18385356
[TBL] [Abstract][Full Text] [Related]
23. Protease inhibitors activity in lepromatous leprosy and lepra reaction.
Yemul VL; Sengupta SR; Dhole TN
Lepr India; 1983 Jan; 55(1):91-4. PubMed ID: 6603564
[TBL] [Abstract][Full Text] [Related]
24. Complement components in kidney allograft recipients: relationship to cytomegalovirus infection.
Chatterjee S; Fiala M; Arroyave C; Azen S; Cosgrove D
J Med Virol; 1982; 9(3):237-44. PubMed ID: 6284872
[TBL] [Abstract][Full Text] [Related]
25. Complement determinations in the synovial fluid and serum of a patient with Erythema nodosum leprosum.
Louie JS; Glovsky M
Int J Lepr Other Mycobact Dis; 1975; 43(3):252-5. PubMed ID: 1240873
[TBL] [Abstract][Full Text] [Related]
26. Serum complement profile in human leprosy and its comparison with immune complex diseases.
Saha K; Chakraborty AK
Int J Lepr Other Mycobact Dis; 1977; 45(4):327-37. PubMed ID: 147246
[TBL] [Abstract][Full Text] [Related]
27. Complement deposition in the skin of patients with herpes-associated erythema multiforme.
Grimwood R; Huff JC; Weston WL
J Am Acad Dermatol; 1983 Aug; 9(2):199-203. PubMed ID: 6350382
[TBL] [Abstract][Full Text] [Related]
28. Activation of complement by circulating immune complexes isolated from leprosy patients.
Tyagi P; Ramanathan VD; Girdhar BK; Katoch K; Bhatia AS; Sengupta U
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):31-8. PubMed ID: 2319186
[TBL] [Abstract][Full Text] [Related]
29. Methods to detect and quantitate complement activation.
Cooper NR; Nemerow GR; Mayes JT
Springer Semin Immunopathol; 1983; 6(2-3):195-212. PubMed ID: 6195745
[No Abstract] [Full Text] [Related]
30. Complement C1q expression in Erythema nodosum leprosum.
Negera E; Walker SL; Lema T; Aseffa A; Lockwood DN; Dockrell HM
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006321. PubMed ID: 29499046
[TBL] [Abstract][Full Text] [Related]
31. Biochemical, immunological and genetic studies in leprosy. II. Profile of immunoglobulins, complement components and C-reactive protein in sera of leprosy patients and healthy controls.
Srivastava LM; Agarwal DP; Goedde HW; Rohde R
Tropenmed Parasitol; 1975 Jun; 26(2):212-8. PubMed ID: 1162738
[TBL] [Abstract][Full Text] [Related]
32. Lepromatous leprosy presenting with polyarthritis, myositis, and immune-complex glomerulonephritis.
Iveson JM; McDougall AC; Leathem AJ; Harris HJ
Br Med J; 1975 Sep; 3(5984):619-21. PubMed ID: 126102
[TBL] [Abstract][Full Text] [Related]
33. Complement changes in falciparum malaria infection.
Phanuphak P; Hanvanich M; Sakulramrung R; Moollaor P; Sitprija V; Phanthumkosol D
Clin Exp Immunol; 1985 Mar; 59(3):571-6. PubMed ID: 3886219
[TBL] [Abstract][Full Text] [Related]
34. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions.
Chakrabarty AK; Kashyap A; Sehgal VN; Saha K
Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112
[TBL] [Abstract][Full Text] [Related]
35. Erythema nodosum leprosum presenting as sweet's syndrome-like reaction in a borderline lepromatous leprosy patient.
Suryawati N; Saputra H
Int J Mycobacteriol; 2018; 7(2):191-194. PubMed ID: 29900900
[TBL] [Abstract][Full Text] [Related]
36. In vitro complement activation by intercellular antibodies.
Hashimoto T; Sugiura M; Kurihara S; Nishikawa T
J Invest Dermatol; 1982 Apr; 78(4):316-8. PubMed ID: 6978365
[TBL] [Abstract][Full Text] [Related]
37. Exacerbation reactions in hyperactive lepromatous leprosy.
Ridley DS; Ridley MJ
Int J Lepr Other Mycobact Dis; 1984 Sep; 52(3):384-94. PubMed ID: 6541206
[TBL] [Abstract][Full Text] [Related]
38. Interactions between the alternative complement pathway and proteases of the coagulation system.
Kazatchkine MD; Jouvin MH
Adv Exp Med Biol; 1984; 167():235-9. PubMed ID: 6561912
[No Abstract] [Full Text] [Related]
39. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
Kerr LD; Adelsberg BR; Schulman P; Spiera H
Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
[TBL] [Abstract][Full Text] [Related]
40. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
